(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Merz: 80% of Syrians in Germany expected to return within three years - 2If you want a true taste of Italian paradise, head to Favignana
- 3Artemis 2 moon rocket gets 'America 250' paint job | Space photo of the day for Dec. 23, 2025
- 4Audits of the Top Science fiction Movies This Year
- 5The 12 biggest space stories of 2025 — according to you
- Opening Monetary Information: Your Exhaustive Manual for Finding out about Individual budget
- Find the Native Culinary Customs: Local Flavors
- Spain’s Picos de Europa: What to see and do in ‘the world’s most beautiful place’
- 15 skywatching events you won't want to miss in 2026
- Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- From Lounge chair to Money: Online Positions That Will Change Your Profession
- Activists guilty over Palestine protest breach
- The Craft of Computerized Detox: Individual Trials
- Why are malnutrition deaths soaring in America?
